Biotoxtech Co Ltd
KOSDAQ:086040
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biotoxtech Co Ltd
Current Portion of Long-Term Debt
Biotoxtech Co Ltd
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Biotoxtech Co Ltd
KOSDAQ:086040
|
Current Portion of Long-Term Debt
₩28.5B
|
CAGR 3-Years
28%
|
CAGR 5-Years
99%
|
CAGR 10-Years
N/A
|
|
|
Samsung Biologics Co Ltd
KRX:207940
|
Current Portion of Long-Term Debt
₩173.6B
|
CAGR 3-Years
-37%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
A
|
ADM Korea Inc
KOSDAQ:187660
|
Current Portion of Long-Term Debt
₩430.2m
|
CAGR 3-Years
-60%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
P
|
Peptron Inc
KOSDAQ:087010
|
Current Portion of Long-Term Debt
₩285.8m
|
CAGR 3-Years
-64%
|
CAGR 5-Years
24%
|
CAGR 10-Years
-18%
|
|
|
S
|
ST Pharm Co Ltd
KOSDAQ:237690
|
Current Portion of Long-Term Debt
₩46.7B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
121%
|
CAGR 10-Years
N/A
|
|
|
L
|
LegoChem Biosciences Inc
KOSDAQ:141080
|
Current Portion of Long-Term Debt
₩1.1B
|
CAGR 3-Years
-52%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
Biotoxtech Co Ltd
Glance View
Biotoxtech Co., Ltd. engages in the provision of non-clinical drug trials. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2007-09-21. The firm provides safety evaluation research, efficacy evaluation research and analysis research. Its safety evaluation research business provides general toxicity tests, local toxicity tests, reproductive and development tests, genotoxicity tests, immunotoxicity tests, carcinogenicity tests, safety pharmacology tests, ecotoxicology tests, histopathology tests and hematology tests. Its efficacy evaluation research business provides efficacy evaluation of medical supplies, health supplements and cosmetics. Its analysis research business provides pharmacokinetics (PK) tests and toxicokinetics (TK) tests services, as well as validation and bio analysis services. On March 13, 2013, the Company acquired a 60% stake in its new established subsidiary.
See Also
What is Biotoxtech Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
28.5B
KRW
Based on the financial report for Sep 30, 2025, Biotoxtech Co Ltd's Current Portion of Long-Term Debt amounts to 28.5B KRW.
What is Biotoxtech Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
99%
Over the last year, the Current Portion of Long-Term Debt growth was 960%. The average annual Current Portion of Long-Term Debt growth rates for Biotoxtech Co Ltd have been 28% over the past three years , 99% over the past five years .
